Constitutive Activation converts RTKs to Dominant Acting Oncogenes Images removed due to copyright reasons. Please see Figure 2 in Zwick,E.,J.Bange and A.Ullrich. "Receptor Tyrosine Kinases as Targets for Anticancer Drugs." Trends Mol Med.8,no.1 (Jan 2002):17-23
Constitutive Activation converts RTKs to Dominant Acting Oncogenes Images removed due to copyright reasons. Please see Figure 2 in Zwick, E., J. Bange and A. Ullrich. Trends Mol Med. 8, no. 1 (Jan 2002):17-23. "Receptor Tyrosine Kinases as Targets for Anticancer Drugs
Genetic alterations leading to Constitutive Activation of RTKs Deletion of extracellular domain Mutations that stimulate dimerization without ligand binding Mutations of Kinase domain .Overexpression of Ligand Overexpression of Receptor
Genetic alterations leading to Constitutive Activation of RTKs • Deletion of extracellular domain • Mutations that stimulate dimerization without ligand binding • Mutations of Kinase domain •Overexpression of Ligand •Overexpression of Receptor
Two Classic Examples Her2 Images removed due to copyright reasons. Please see Lodish,Harvey,et.al.Molecular Cell Biology. 5th ed.New York:W.H.Freeman and Company,2004. receptor EGF receptor Her2 Human Epidermal growth factor receptor 2 EGFR Epidermal growth factor receptor
Two Classic Examples Her2 receptor EGF receptor Her2 = Human Epidermal growth factor receptor 2 EGFR = Epidermal growth factor receptor Images removed due to copyright reasons. Please see Lodish, Harvey, et. al. Molecular Cell Biology. 5th ed. New York : W.H. Freeman and Company, 2004